Abstract
OBJECTIVE: To probe into the effects of amiodarone and esmolol for heart rate disorders and myocardial infarction. METHODS: 76 cases of cardiopathy in our hospital from July 2019 to October 2021 were analyzed for myocardial infarction. The control group applied amiodarone treatment. Blood pressure, treatment effect, adverse reactions, myocardial marker levels, electrocardiogram, and heart function indicators were compared. RESULTS: There were no statistical differences in two groups of diastolic pressure (P > 0.05). The analysis of the systolic pressure in the study group was greater than the control group (P < 0.05); The effective rate was higher than that of the control group (P < 0.05); the incidence of adverse reactions in the study group and control group was 28.95% and 31.58%, respectively, and there was no statistically significant difference between groups (P > 0.05). The standards of markers were significantly reduced compared with the control group (P < 0.05). After treatment, the heart rate of the two groups was significantly reduced, and the QT intervals were significantly shortened. But compared with the control group, reduction was larger in the research group (P < 0.05). Compared with the control group, the resolution rate was higher (P < 0.05). After treatment, the two groups of quality of life were significantly increased, and compared with the control group, the increase in the quality of life of the study group was greater (P < 0.05). CONCLUSION: Application of amiodarone and esmolol joint treatment can improve the quality of life, improve the level of heart function and myocardial marker, and can reduce Q-T intervals and prognosis. Therefore, amiodarone and esmolol treatment is worth promoting.